Release no. 23/2011

Copenhagen and Oslo, 24th November, 2011, 2011-11-24 20:05 CET (GLOBE NEWSWIRE)
--
-- Completion of preclinical development of anti-VEGF antibody AT001/r84
-- Anti-CCR4 antibody selected as first development candidate from anti-GPCR
antibody research program
-- Estimated net loss for 2011 of DKK 45-55 million, changed from DKK 50-60
million previously announced
-- Cash reserves of DKK 12.8 million as per 30th September 2011
-- Net loss for the first nine months DKK 51.1 million


In addition the Company reports key events following the end of the quarter:


-- Development milestone payment for AT001/r84 of EUR 2.5 million received
from IBC Generium
-- New focus on product development resulting in staff reduction
-- Voluntary conditional public purchase offer to Affitech's shareholders from
Trans Nova Investments Limited of DKK 0.22 per share



Affitech A/S, (NASDAQ OMX: AFFI), the antibody medicines company, today
reported the financial result of the third quarter of 2011. Affitech generated
a loss for the first nine months of 2011 of DKK 51.1 million and had cash of
DKK 12.8 million as of 30th September 2011.


Highlights of the third quarter of 2011


-- Fully human antibody AT001/r84, an anti‐angiogenesis development compound,
completed pre-clinical testing satisfactorily and is ready for human
clinical testing. Details provided in the section “Progress with AT001/r84”
below.


-- Affitech's first anti-GPCR antibody program AT008, designed to block the
binding of chemokine ligands to its cell surface receptor CCR4, is in
preclinical pharmacology testing. The program includes several different
antibodies with multiple potential mechanisms of action targeting
hematological cancers and solid tumors, either directly, through metastatic
lesions and/or regulatory T cells. It also has potential utility in some
immunological diseases such as severe asthma.

-- Preliminary proof of concept has been demonstrated in a T cell lymphoma
xenograph model.
-- A development candidate has been identified.
-- Development of an AT008 manufacturing cell line is ongoing


-- Six other chemokine receptor programs are being produced and profiled.
-- Affitech continued the development of its own in-house bi-specific antibody
program.


-- On 14th July, 2011, Affitech A/S announced two major shareholder
transactions agreements:


-- Trans Nova Investments Ltd. reduced the number of shares in Affitech A/S
from 260,187,010 shares of each DKK 0.50/number of voting rights (equal to
53.34% of Affitech A/S' total share capital /number of voting rights) to
195,140,258 shares of each DKK 0.50 equal to 40% of Affitech A/S' total
share capital/number of voting rights.


-- Krosalter Enterprises Ltd. Cyprus acquired 65,046,752 shares in Affitech
A/S of a nominal value of 0.50 DKK each equal to 13.34% of the total share
capital/number of voting rights.


-- On 30th September, 2011, Affitech A/S announced that Dr Martin Welschof,
its Managing Director, would leave his position at the end of the year. The
Board of Directors accepted his resignation with effect from 31st December,
2011.



Progress with AT001/r84


AT001/r84 is a fully human antibody that binds to vascular endothelial growth
factor A (VEGF-A), a drug target validated clinically and commercially by
bevacizumab (Avastin®). Bevacizumab is a humanized monoclonal mouse antibody
whereas the Affitech product is a fully human antibody with more selective
binding site properties than bevacizumab and different affinity to VEGF-A.
Higher selectivity and altered affinity offer potential for an increased
safety/efficacy profile when compared to the bevacizumab in the treatment of
human cancer.


Manufacturing

AT001/r84 is a recombinant human antibody and produced as a biological using
large scale cultured mammalian cells. Several manufacturing runs under Good
Manufacturing Practice (GMP) standards have been completed this year and
multi-kilogram amounts of the antibody have been produced as active
pharmaceutical ingredient. Analytical methods have been developed and the GMP
antibody has passed a variety of required quality and stability tests. Drug
product in sterile vials has been released and is ready for human
administration. A new production cell line has been developed that is expected
to result in improved production efficiency at larger scales and discussions
with contract manufacturing companies to scale up manufacturing are ongoing.


Preclinical development

Pre-clinical testing of AT001/r84 has been completed which is expected to
enable IBC Generium to submit a Clinical Trial Application for phase I clinical
trials in Russia. The preclinical information package included satisfactory
pharmacokinetic, pharmacological and immu­nological assay results, as well as
the data from 28 day rat and non-human primate toxicological studies performed
to Good Laboratory practice (GLP) standards. Results from these GLP toxicology
studies showed that high doses of AT001/r84 antibody were well tolerated. A
number of animal model efficacy studies have also been conducted that confirm
the anti-angiogenic properties of the drug and support entry of AT001/r84 into
human phase 1 clinical trial. Long term GLP toxicology and stability studies
will be required for phase II clinical trials and these have recently been
initiated.


Clinical

The clinical strategy for AT001/r84 is to develop the product for improved
treatment of patients with various cancer sub-types known to be susceptible to
anti-angiogenesis therapy, such as metastatic colorectal cancer, including
co-administration with chemotherapy and other anticancer treatments. The first
human clinical study will involve administration of single doses of the
antibody to cancer patients to assess human safety and dosage levelling and
Affitech's Russian development partner, IBC Generium, has informed the Company
that it is preparing an application to the Russian health authorities for
regulatory approval to conduct such a phase 1 study.


Commercial

The pharmaceutical anti-angiogenesis market is large with world wide sales
approaching $15 billion and revenues from bevacizumab (Avastin®) in 2010 of
approximately $7 billion. AT001/r84 has the potential to have similar efficacy
to bevacizumab with an improved safety profile. However, the properties and
potential of AT001/r84 have yet to be confirmed through human clinical studies
and until such data is available, it is not possible to make meaningful
estimates for the probability of achieving marketing approval in different
territories nor potential market size or share. Nevertheless, the validity of
the anti-angiogenic approach for treating human cancers and certain other
conditions is well recognised. Several new anti-angiogenic drugs have recently
been approved for human use, while others are in late stage clinical
development by a variety of pharmaceutical and biopharmaceutical companies.



Subsequent events after the end of the reporting period 30th September, 2011


-- On 12th October, 2011 Affitech A/S announced that the U.S. Patent and
Trademark Office (USPTO) has granted Affitech U.S. patent (no. 8,034,905)
covering the Company's leading anti-VEGF antibody drug candidate AT001/r84.
This US patent is the first patent grant Affitech has received for this
compound in a major territory and it considerably strengthens Affitech's IP
position regarding this drug candidate. The patent is co-owned by Affitech
and its collaboration partner Peregrine Pharmaceuticals.


-- On 17th October 2011 Affitech A/S announced that GE Healthcare Life
Sciences has executed an exclusive license for the worldwide marketing and
sales of products containing recom­binant Protein L, granted by Affitech in
a patent and know-how license agreement. Under the terms of the agreement,
GE Healthcare Life Sciences agrees to pay Affitech a royalty on net sales
of all related products sold by GE Healthcare Life Sciences.


-- On 20th October, 2011 Affitech A/S announced that the Company had received
2.5 million Euro in milestone payment from IBC Generium. The payment is
related to the delivery of the preclinical package for Affitech's anti VEGF
antibody AT001/r84 to its Russian collaboration partner IBC Generium, who
will use the package for the filing of a Clinical Trial Application (CTA)
in Russia. AT001/r84 is a novel patented human mono­clonal antibody to
human vascular endothelial growth factor (VEGF), and is being developed as
a potential treatment of cancer. The collaboration agreement with IBC
Generium comprises two development projects and is worth up to € 23 million
in fees and advanced royalties to Affitech.


-- On 17th November, 2011 Affitech announced a restructuring of the Company
resulting in a staff reduction of about 24 people at the Company's
subsidiary, Affitech Research AS in Oslo, where its main Research and
Development operations take place. The reasons for this restructuring
exercise are (i) to focus more of its spending on development of its lead
antibody products and (ii) to extend the period available to the Company
for raising fresh capital.


-- On 21st November, 2011, Affitech's shareholders received a voluntary
conditional public purchase offer of DKK 0.22 per share from Trans Nova
Investments Limited. For information on the offer, see the Company's
announcement of 21st November 2011 and the Offer Document available via
the Affitech A/S website, www.affitech.com


Outlook for 2011

The financial outlook for 2011 is changed to an estimated loss of DKK 45-55
million compared to a loss of DKK 50-60 million as previously announced. This
includes restructuring expenses of up to DKK 5 million offset by a general
lower operating cost level than previously expected in Q3 and Q4 and the
initial impact of the cost saving measures taken. The cash position at year end
2011 is expected to be in the range of DKK 25 million. The annual cost saving
effects of the announced restructuring is estimated to be DKK 18 million.


As of 30th September 2011 Affitech has made payments of DKK 28 million to
outsourced contract manufacturing companies for supplies of AT001/ r84 drug
material made to Good Manu­facturing Practice (GMP) standards for use in
pre-clinical and clinical trials. This amount is included in the balance sheet
under Other Current Assets. IBC Generium will use the main part of this GMP
drug product in long term toxicology investigations, stability studies and
human clinical trials in Russia and is committed to reimburse Affitech for the
fully burdened manufacturing costs of their share of the material during 2011
and 2012.


During the fourth quarter of 2011, Affitech expects to:

-- Confirm that IBC Generium has filed a regulatory application in Russia for
approval for the first clinical trial with AT001/r84, expected to commence
in 2012.
-- Expand pharmacological testing of potential drug candidates in the AT008
program targeting CCR4 to models of solid tumors and metastatic diseases.
-- Continue optimization of the proprietary CBAS(TM) technology platform
through advances in quality control and improved new antibody libraries.
-- Identify the next anti-GPCR program likely to result in the Company's third
development candidate.
-- Implement the restructuring program to reduce internal and external
expenses.
-- Receive additional license fee revenues from IBC Generium of EUR 2.0
million, in addition to the EUR 2.5 million milestone payment received on
20th October, 2011, resulting in total license and milestone revenues from
IBC Generium in the 4th Quarter of EUR 4.5 million.


Financial Considerations related to the restructuring announced 17h November,
2011

Affitech announced in its Q2 2011 report that the Company would require further
financing by the end of Q1 2012 in order to pursue its present activities.
Trans Nova Investments has indicated to Affitech's Board of Directors that they
do not intend to solely fund Affitech's further activities at the present rate
of cash utilization. As a result, the Company has investigated potential
co-investor leads for financing, and this process will continue for the coming
months. The Board of Affitech views the quality of the Company's technology and
new product opportunities as very strong and believes that the company has the
basis and the competitive edge for further financing its Research and
Development. However, due to the currently difficult financial market, a new
financing process is likely to take time and cannot be guaranteed. The Board of
Affitech has therefore decided to reduce expenses and cash utiliza­tion in
order to extend the period during which the Company can continue its operations
while seeking new investment on an international basis. By implementing the
staff reductions announced on 17th November, 2011 and other cost cutting
measures and focusing its activities on the development programs, the Board of
Directors expects the Company to have sufficient funds until at least the end
of Q2 2012.


Comments from the Board to the offer from Trans Nova Investments Limited

The Board of Directors has been fully informed of the details of Trans Nova's
voluntary conditional public purchase offer to shareholders announced on 21st
November, 2011. However, no discussion has been held with Trans Nova
concerning the price of the Offer and no advice in relation to the Offer has
been sought from Affitech's Board of Directors. Shareholders must come to
their own decision as to whether or not to accept the Offer and the Board of
Directors does not intend to give an opinion.



Contact:

Randi Krogsgaard, Director IR & Corporate Communications

Tel # +45 2320 1001, e-mail: [email protected]





About Affitech

Affitech A/S is a publicly traded (NASDAQ OMX Copenhagen) human therapeutic
antibody company based in Copenhagen, Denmark with R&D facilities in Oslo,
Norway. The company utilizes a range of proprietary antibody technologies for
the discovery of fully human antibodies for application in oncology,
inflammation and other disease areas. CBAS™ (Cell Based Antibody Selection) is
Affitech's premier discovery engine for the isolation of lead antibodies to
cell surface molecules. Affitech co-develops its two lead antibody drug
programs AT001/r84 and AT008/CCR4 with Russian partner IBC Generium. The
Company's initial focus is on rapid and cost effective development by
partnering clinical trials in emerging markets. Further information is
available at www.affitech.com.


Disclaimer
This announcement may contain forward-looking statements including statements
about Affitech's expectations of the progression of its pipeline including the
timing for commencement and completion of clinical trials and with respect to
cash burn guidance. Such statements are based on management's current
expectations and are subject to a number of risks and uncertainties that could
cause actual results to differ materially from those described in the
forward-looking statements. Affitech cautions investors that there can be no
assurance that actual results or business conditions will not differ materially
from those projected or suggested in such forward-looking statements as a
result of various factors, including, but not limited to, the following: risks
associated with technological development, the risk that research & development
will not yield new products that achieve commercial success, the impact of
competition, the ability to transact viable and profitable commercial deals,
the risk of non-approval of patents not yet granted, and difficulties of
obtaining relevant governmental approvals for new products.

No expressed or implied representations or warranties are given concerning
Affitech A/S or the accuracy or completeness of the information provided
herein, and no claims shall be made by the recipient of this news release by
virtue of the information contained herein.

111124 FINAL PR 23 3rd Quarter 2011 Report UK.pdf